Standard BioTools
LAB
80 hedge funds and large institutions have $106M invested in Standard BioTools in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 6 closing their positions.
62% more call options, than puts
Call options by funds: $606K | Put options by funds: $375K
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
8% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 25
0% more funds holding
Funds holding: 80 → 80 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.15% less ownership
Funds ownership: 92.9% → 89.74% (-3.2%)
31% less capital invested
Capital invested by funds: $154M → $106M (-$48.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.9M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$737K |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$424K |
| 4 |
Millennium Management
New York
|
+$406K |
| 5 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$405K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.59M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.51M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$1.47M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$855K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$570K |
LAB Hedge Fund Activity: Q2 2017 in Review
80 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q2 2017, worth a combined $106M — down 31% from $154M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new LAB positions and 6 closed out — a net gain of 1 holder — while 27 added to existing stakes and 25 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $1.9M. The largest seller was Wellington Management Group, exiting entirely with an estimated $3.59M sold.
- 80 institutional investors held Standard BioTools (LAB) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $106M of Standard BioTools stock for Q2 2017, down 31% quarter-over-quarter.
- 7 funds opened new Standard BioTools positions in Q2 2017 and 6 closed out, a net change of +1 holder.
- The largest Standard BioTools buyer in Q2 2017 was Adage Capital Partners, an estimated $1.9M added.
- The largest Standard BioTools seller in Q2 2017 was Wellington Management Group, an estimated $3.59M sold.
Based on aggregated 13F filings for Q2 2017.